Novel OCTN2 mutations: no genotypephenotype correlations: early carnitine therapy prevents cardiomyopathy
Testing : Select products that are third-party tested for safety and efficacy
Anyaoku is licensed in California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky, Louisiana, Maine, Michigan, Montana, Nevada, New Jersey, New York, New Hampshire, North Carolina, Ohio, Pennsylvania, Tennessee, Texas, Virginia, and Wisconsin
Preclinical and early human data suggest it may promote lipolysis, inhibit lipogenesis, and preferentially act on adipose tissue by influencing beta3 adrenergicmediated pathways and hormonesensitive lipase activity